MUMBAI - India's top drug maker Ranbaxy Laboratories could be ready to team up with Israel's Teva Pharmaceuticals for an "at risk" launch of a generic version of AstraZeneca's heartburn blockbuster Nexium (esomeprazole), following tentative U.S. approval last month, Indian analysts say
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
Oral RNA splicing modulator has gone into a Phase II/III trial
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
